prostate cancer Articles
-
Low-dose irradiation for controlling prostate cancer
Prostate cancer is the second most commonly diagnosed cancer among North American men and the second leading cause of death in those aged 65 and over. The US Cancer Society recommends testing those over 50 years of age who are expected to live at least for 10 years, even though the ability of early detection to decrease prostate cancer mortality has not been demonstrated. A controversy exists ...
-
Design and analysis of nanowire sensor array for prostate cancer detection
Prostate cancer is one of the major cancer affecting men in India. After lung cancer, prostate cancer has caused large number of deaths in India. Nanowire is the biosensor used for detection of cancer. In this paper, we present a design of nanowire array sensor for prostate cancer detection. A sensor array of 8 × 8 elements is designed to capture the PSA present in the blood that helps in ...
-
Movember Together: How Paige, University of Oxford, and Prostate Cancer UK Are Working to Change the Prostate Cancer Experience
Movember is an annual initiative where men from around the globe grow mustaches to raise awareness for men’s health causes, including mental health and suicide prevention, testicular cancer, and prostate cancer. Through events, fundraising, and using mustaches as a light-hearted starting point for important conversations, the movement supports men in taking charge of their health to live ...
-
Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer
Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site ...
-
Bio-tech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer biopsies. Private research company Nanostics Inc. and the University of ...
-
Nanostics Receives CE Mark for its ClarityDX Prostate Test to Detect Clinically Significant Prostate Cancer
Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark. A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries. The ClarityDX Prostate® test provides patients ...
-
Phase lb study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors and are currently approved for ovary, breast, pancreas and prostate cancers. VASTUS study (NCT04174716)1' is a basket trial investigating the safety and efficacy of venadaparib in 6 cohorts (active recruiting) of different tumors, including breast ...
-
Partech Movember Challenge!
This November six members of the Partech team will be growing and grooming moustaches in aid of the ‘Movember Foundation’.The ‘Movember Foundation’ is a global charity committed to men living happier, healthier and longer lives. The charity was set up in 2003 and since then millions have joined the men’s health movement raising £443 million and funding over ...
-
First-in-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP inhibitor, in Patients with Advanced Solid Tumors
Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors known as single-strand breaks. PARP inhibitors are currently approved (or ovary, breast, pancreatic and prostate cancers which harbor BRCA1/2 mutations and/or homologous recombinant repair mutation. In this phase 1 dose escalation study of venadaparib, we determined the maximum tolerated dose ...
-
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the clinical validation study This partnership will ...
-
Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment
Abstract Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen. Materials and methods: We developed a ...
By MDxHealth
-
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: The study population consisted of 211 AA men from 7 urology centers ...
By MDxHealth
-
Acibadem Hospitals Digital Pathology Project - Case study
Virasoft provides digital pathology systems that optimize the pathology workflow with digital slide management, slide viewing and quantitative image analysis for Acibadem Hospitals pathology laboratories. In partnership with Acibadem Hospitals and Virasoft, artificial intelligence projects are being developed for several cancer diagnosis. Digital Pathology System ViraCenter is an integrated ...
-
How Has the COVID-19 Pandemic Affected Prostate Cancer Care?
#CancelEverything On March 11, 2020, the World Health Organization (WHO) declared the coronavirus 2019 disease (COVID-19) a global pandemic. Its impact left the world uncertain about health, politics and the economy. The first wave caused a major disruption to health services, exacerbating concerns of patient and physician safety and resource availability. On trend with the “cancel ...
-
Case Study B - Liquid Biopsy
X-ZELL is collaborating with Singapore General Hospital (SGH) and the National University Hospital Singapore (NUH) to explore how X-ZELL single-cell diagnostics may aid in the early detection of clinically significant prostate cancer in whole blood. The prospectively blinded, 400-patient multi-centre study officially commenced in 2020 and will lay the foundation for the launch of a commercially ...
By X-Zell Inc.
-
Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.
Organizations Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, MDxHealth, B.V., Nijmegen, Netherlands, MDxHealth, Inc., Irvine, CA, Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium, Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany Abstract ...
By MDxHealth
-
The correlation of hypersensitivity for HRS/IRR and the 'inverse' dose-rate effect – its potential influence on LDR brachytherapy: a review
The 'Inverse' Dose-Rate Effect (IDRE) has been extensively studied (Leonard, 2000; 2007a; Leonard and Lucas, 2008a?b). We here consolidate these results. We have shown a correlation between Hyper-radiosensitivity and the Induced Radioresistance effect (HRS/IRR), and IDRE has the same threshold and transition behaviours. This supports a conclusion that IDRE is the dose-rate manifestation of ...
-
Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer
Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America. The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform. The study is supported in part by the Alberta Innovates AICE-Concepts Program with a ...
-
EDAP Announces Exclusive Worldwide Distribution Rights to Exact Imaging’s Micro-Ultrasound Technologies
Exact Imaging is a leading developer of ultra-high-resolution micro-ultrasound diagnostic technologies Micro-ultrasound ExactVu™ is the only ultrasound-based imaging tool with published data demonstrating prostate cancer diagnostic capabilities similar to MRI Combination of Exact Imaging’s micro-ultrasound and EDAP’s Focal One® represents the most complete offering for ...
-
Intraoperative Identification and Monitoring of the Somatic Nerves Critical to Potency Preservation during da Vinci Prostatectomy
Background Since Walsh and Donker first introduced the anatomic nerve-sparing technique for retropubic radical prostatectomy1 (RRP) in the treatment of clinically localized prostate cancer, the importance of minimizing damage to the neurovascular bundle (NVB) has been recognized as a critical element for the preservation of potency and urinary continence post-prostatectomy. Although originally ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you